Letter
Hypersensitivity reactions to carboplatin given to patients with relapsed ovarian carcinoma

https://doi.org/10.1016/0959-8049(94)90489-8Get rights and content

References (9)

There are more references available in the full text version of this article.

Cited by (61)

  • Outpatient desensitization in selected patients with platinum hypersensitivity reactions

    2017, Gynecologic Oncology
    Citation Excerpt :

    Once workers developed these symptoms, they were always symptomatic in platinum-containing environments; however, it was also noted that patients could be systematically desensitized. It has been postulated that HSR are type I, immunoglobin E (IgE) mediated hypersensitivity reactions [16]. In type I hypersensitivity reactions, IgE bound to mast cells and basophils become activated causing cross-linking of the IgE ultimately resulting in release of pharmacologically active mediators including histamine, leukotrienes and prostaglandins [8].

  • Cisplatin can be safely administered to ovarian cancer patients with hypersensitivity to carboplatin

    2017, Gynecologic Oncology
    Citation Excerpt :

    About 70% of patients with a platinum sensitive recurrence are rechallenged with a carboplatin-based regimen and a considerable amount of patients receiving carboplatin will eventually experience an HSR [2–4]. Several studies have tried to determine typical HSR patterns of presentation and related risk factors [6–17]; however, mechanisms underlying such reactions are still poorly understood, even if both an immediate type IgE mediated hypersensitivity reaction and a direct action of platinum on mast cells, leading to the release of vasoactive substances, are thought to play a relevant role. The risk of developing HSR has been reported to increase with the number of carboplatin lines and is estimated to be < 1% during first line, and as high as 27% in patients treated with more than seven cycles of therapy.

  • Decreased hypersensitivity reactions with carboplatin-pegylated liposomal doxorubicin compared to carboplatin-paclitaxel combination: Analysis from the GCIG CALYPSO relapsing ovarian cancer trial

    2011, Gynecologic Oncology
    Citation Excerpt :

    The global rate of hypersensitivity (24.6%) observed in the CALYPSO trial is consistent with that reported in the literature for the combinations as well as with that observed in studies of retreatment with single-agent carboplatin [22–26]. In the rechallenge setting, the incidence of carboplatin HSRs can exceed 20% [20,27]. Hence, a number of researchers have attempted to investigate predictive factors to identify patients who are likely to develop hypersensitivity [7,9,16,20,21,28–30].

View all citing articles on Scopus
View full text